Dusan Hadzi-Pavlovic

Dusan Hadzi-Pavlovic

Auto-generated profile, based on publicly available information

Dusan Hadzi-Pavlovic

Affiliation Discipline of Psychiatry and Mental Health, School of Clinical Medicine, UNSW, Sydney, Australia

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in Public Health Reviews
Verified
Journal Article
Open access
PTP. Tavakoli
P. Tavakoli
UVU. Vollmer-Conna
U. Vollmer-Conna
DHD. Hadzi-Pavlovic
D. Hadzi-Pavlovic
MGM. C. Grimm
M. C. Grimm
Objective: Inflammatory bowel diseases (IBDs) are complex chronic inflammatory disorders of the gastro-intestinal (GI) tract with uncertain etiology. IBDs comprise two idiopathic disorders: Crohn’s disease (CD) and ulcerative colitis (UC). The aetiology, severity and progression of such disorders are still poorly understood but thought to be influenced by multiple factors (including genetic, environmental, immunological, physiological, psychological factors and gut microbiome) and their interactions. The overarching aim of this review is to evaluate the extent and nature of the interrelationship between these factors with the disease course. A broader conceptual and longitudinal framework of possible neuro-visceral integration, core microbiome analysis and immune modulation assessment may be useful in accurately documenting and characterizing the nature and temporal continuity of crosstalk between these factors and the role of their interaction (s) in IBD disease activity. Characterization of these interactions holds the promise of identifying novel diagnostic, interventions, and therapeutic strategies.Material and Methods: A search of published literature was conducted by exploring PubMed, EMBASE, MEDLINE, Medline Plus, CDSR library databases. Following search terms relating to key question were set for the search included: “Inflammatory bowel diseases,” “gut microbiota,” “psychological distress and IBD,” “autonomic reactivity and IBD,” “immune modulation,” “chronic inflammation,” “gut inflammation,” “enteric nervous system,” “gut nervous system,” “Crohn’s disease,” “Ulcerative colitis”, “depression and IBD”, “anxiety and IBD”, “quality of life in IBD patients,” “relapse in IBDs,” “remission in IBDs,” “IBD disease activity,” “brain-gut-axis,” “microbial signature in IBD,” “validated questionnaires in IBD,” “IBD activity indices,” “IBD aetiology,” “IBDs and stress,” “epidemiology of IBDs”, “autonomic nervous system and gut inflammation”, “IBD and environment,” “genetics of IBDs,” “pathways of immune response in IBDs,” “sleep disturbances in IBD,” “hypothalamic-pituitary-adrenal axis (HPA),” “sympatho-adrenal axis,” “CNS and its control of gut function” “mucosal immune response,” “commensal and pathogenic bacteria in the gut,” “innate and adaptive immunity.” Studies evaluating any possible associations between gut microbiome, psychological state, immune modulation, and autonomic function with IBDs were identified. Commonly cited published literatures with high quality research methodology/results and additional articles from bibliographies of recovered papers were examined and included where relevant.Results: Although there is a substantial literature identifying major contributing factors with IBD, there has been little attempt to integrate some factors over time and assess their interplay and relationship with IBD disease activity. Such contributing factors include genetic and environmental factors, gut microbiota composition and function, physiological factors, psychological state and gut immune response. Interdependences are evident across psychological and biological factors and IBD disease activity. Although from the available evidence, it is implausible that a single explanatory model could elucidate the interplay between such factors and the disease course as well as the sequence of the effect during the pathophysiology of IBD.Conclusion: Longitudinal monitoring of IBD patients and integrating data related to the contributing/risk factors including psychological state, physiological conditions, inflammatory/immune modulations, and microbiome composition/function, could help to explain how major factors associate and interrelate leading to exacerbation of symptoms and disease activity. Identifying the temporal trajectory of biological and psychosocial disturbances may also help to assess their effects and interdependence on individuals’ disease status. Moreover, this allows greater insight into understanding the temporal progressions of subclinical events as potential ground for disease severity in IBD. Furthermore, understanding the interaction between these risk factors may help better interventions in controlling the disease, reducing the costs related to disease management, further implications for clinical practice and research approaches in addition to improving patients’ mental health and quality of life.

1 November 2017 in Clinical Psychology Review
Verified
Journal Article
Closed access
MOMeaghan O’Donnell
Meaghan O’Donnell
ISIngo Schaefer
Ingo Schaefer
TVTracey Varker
Tracey Varker
Dzenana KartalDzenana Kartal
Dzenana Kartal
DFDavid Forbes
David Forbes
ZSZachary Steel
Zachary Steel

25 February 2016 in JMIR Mental Health
Verified
Journal Article
Open access
JCJanine Clarke
Janine Clarke
JPJudith Proudfoot
Judith Proudfoot
AWAlexis Whitton
Alexis Whitton
MBMary-Rose Birch
Mary-Rose Birch
MBMegan Boyd
Megan Boyd
AFAndrea Fogarty
Andrea Fogarty
Background: Studies of Internet-delivered psychotherapies suggest that clients report development of a therapeutic alliance in the Internet environment. Because a majority of the interventions studied to date have been therapist-assisted to some degree, it remains unclear whether a therapeutic alliance can develop within the context of an Internet-delivered self-guided intervention with no therapist support, and whether this has consequences for program outcomes. Objective: This study reports findings of a secondary analysis of data from 90 participants with mild-to-moderate depression, anxiety, and/or stress who used a fully automated mobile phone and Web-based cognitive behavior therapy (CBT) intervention called “myCompass” in a recent randomized controlled trial (RCT). Methods: Symptoms, functioning, and positive well-being were assessed at baseline and post-intervention using the Depression, Anxiety and Stress Scale (DASS), the Work and Social Adjustment Scale (WSAS), and the Mental Health Continuum-Short Form (MHC-SF). Therapeutic alliance was measured at post-intervention using the Agnew Relationship Measure (ARM), and this was supplemented with qualitative data obtained from 16 participant interviews. Extent of participant engagement with the program was also assessed. Results: Mean ratings on the ARM subscales were above the neutral midpoints, and the interviewees provided rich detail of a meaningful and collaborative therapeutic relationship with the myCompass program. Whereas scores on the ARM subscales did not correlate with treatment outcomes, participants’ ratings of the quality of their emotional connection with the program correlated significantly and positively with program logins, frequency of self-monitoring, and number of treatment modules completed (r values between .32-.38, P≤.002). The alliance (ARM) subscales measuring perceived empowerment (r=.26, P=.02) and perceived freedom to self-disclose (r=.25, P=.04) also correlated significantly in a positive direction with self-monitoring frequency. Conclusions: Quantitative and qualitative findings from this analysis showed that a positive therapeutic alliance can develop in the Internet environment in the absence of therapist support, and that components of the alliance may have implications for program usage. Further investigation of alliance features in the Internet environment and the consequences of these for treatment outcomes and user engagement is warranted. Trial Registration: Australian New Zealand Clinical Trials Registry Number (ACTRN): 12610000625077; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335772&isReview=true (Archived by WebCite at http://www.webcitation.org/6efAc5xj4).

4 March 2015 in JMIR Mental Health
Verified
Journal Article
Open access
AWAlexis Whitton
Alexis Whitton
JPJudith Proudfoot
Judith Proudfoot
JCJanine Clarke
Janine Clarke
MBMary-Rose Birch
Mary-Rose Birch
GPGordon Parker
Gordon Parker
DHDusan Hadzi-Pavlovic
Dusan Hadzi-Pavlovic
Background: Internet-delivered mental health (eMental Health) interventions produce treatment effects similar to those observed in face-to-face treatment. However, there is a large degree of variation in treatment effects observed from program to program, and eMental Health interventions remain somewhat of a black box in terms of the mechanisms by which they exert their therapeutic benefit. Trials of eMental Health interventions typically use large sample sizes and therefore provide an ideal context within which to systematically investigate the therapeutic benefit of specific program features. Furthermore, the growth and impact of mobile phone technology within eMental Health interventions provides an opportunity to examine associations between symptom improvement and the use of program features delivered across computer and mobile phone platforms. Objective: The objective of this study was to identify the patterns of program usage associated with treatment outcome in a randomized controlled trial (RCT) of a fully automated, mobile phone- and Web-based self-help program, “myCompass”, for individuals with mild-to-moderate symptoms of depression, anxiety, and/or stress. The core features of the program include interactive psychotherapy modules, a symptom tracking feature, short motivational messages, symptom tracking reminders, and a diary, with many of these features accessible via both computer and mobile phone. Methods: Patterns of program usage were recorded for 231 participants with mild-to-moderate depression, anxiety, and/or stress, and who were randomly allocated to receive access to myCompass for seven weeks during the RCT. Depression, anxiety, stress, and functional impairment were examined at baseline and at eight weeks. Results: Log data indicated that the most commonly used components were the short motivational messages (used by 68.4%, 158/231 of participants) and the symptom tracking feature (used by 61.5%, 142/231 of participants). Further, after controlling for baseline symptom severity, increased use of these alert features was associated with significant improvements in anxiety and functional impairment. Associations between use of symptom tracking reminders and improved treatment outcome remained significant after controlling for frequency of symptom tracking. Although correlations were not statistically significant, reminders received via SMS (ie, text message) were more strongly associated with symptom reduction than were reminders received via email. Conclusions: These findings indicate that alerts may be an especially potent component of eMental Health interventions, both via their association with enhanced program usage, as well as independently. Although there was evidence of a stronger association between symptom improvement and use of alerts via the mobile phone platform, the degree of overlap between use of email and SMS alerts may have precluded identification of alert delivery modalities that were most strongly associated with symptom reduction. Future research using random assignment to computer and mobile delivery is needed to fully determine the most ideal platform for delivery of this and other features of online interventions. Trial Registration: Australian New Zealand Clinical Trials Registry (ACTRN): 12610000625077; http://www.anzctr.org.au/TrialSearch.aspx? (Archived by WebCite http://www.webcitation.org/6WPqHK0mQ).

24 October 2000 in Social Psychiatry and Psychiatric Epidemiology
Verified
Journal Article
Closed access
PDF file
DHD. Hadzi-Pavlovic
D. Hadzi-Pavlovic
IHI. B. Hickie
I. B. Hickie
AWA. J. Wilson
A. J. Wilson
TDT. A. Davenport
T. A. Davenport
ALAndrew Lloyd
Andrew Lloyd
DWD. Wakefield
D. Wakefield

21 May 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JCJanine Clarke
Janine Clarke
SSSanatkar Samineh
Sanatkar Samineh
PBPeter Baldwin
Peter Baldwin
SFSusan Fletcher
Susan Fletcher
JGJane Gunn
Jane Gunn
JPJudy Proudfoot
Judy Proudfoot
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Depressive symptoms are common in people with type 2 diabetes and exacerbate disease burden through increased social and occupational impairment and greater morbidity and mortality. Effective depression treatments exist, however rates of depression screening in type 2 diabetes are variable, access to psychological support is characteristically low, and impact of treatment on daily functioning remains unclear. Web-based cognitive behaviour therapy (CBT) is easily accessible, private, non-stigmatising and a potential solution to reducing the substantial personal and public health impact of comorbid type 2 diabetes and depression. Objective: To evaluate the efficacy of the web-based CBT program, myCompass, for improving social and occupational functioning in a large community sample of people with type 2 diabetes and self-reported mild-to-moderate depressive symptoms. myCompass is an unguided, public health treatment program for common mental health problems. Impact of treatment on depressive symptoms, diabetes-related distress, anxiety symptoms and self-care behaviour was also examined. Methods: Participants with type 2 diabetes and mild-to-moderate depressive symptoms (N = 780) were recruited online and via community and general practice settings. Screening, consent and data collection were conducted online, and randomisation was to either myCompass (n = 391) for 8 weeks plus a 4-week tailing off period, or an active placebo intervention (n = 379). At baseline and post-intervention (3-months), participants completed the Work and Social Adjustment Scale (WSAS), the primary outcome measure. Secondary outcome measures included the Patient Health Questionnaire-9 item (PHQ-9), Diabetes Distress Scale (DDS), Generalised Anxiety Disorder Questionnaire-7 item (GAD-7) and items from the Self-Management Profile for Type 2 Diabetes (SMP-T2D). Results: At baseline, mean scores on several outcome measures, including the primary outcome of work and social functioning, were near to the normal range, despite a varied and extensive recruitment process. Of the 780 trial participants, 473 (61%) completed the post-intervention assessment. Intention-to-treat analyses revealed improvement in functioning, depression, anxiety, diabetes distress and healthy eating over time in both groups. Except for blood glucose monitoring and medication adherence, there were no specific between-group effects. Follow-up analyses suggested the outcomes did not depend on age, morbidity or treatment engagement. Conclusions: Improvement in social and occupational functioning and the secondary outcomes was generally no greater for myCompass users than users of the control program at 3 months post-intervention. These findings should be interpreted in light of near-normal mean baseline scores on several variables, the self-selected study sample and sample attrition. Further attention to factors influencing uptake and engagement with mental health treatments by people with type 2 diabetes, and the impact of illness comorbidity on patient conceptualisation and experience of mental health symptoms, is essential to reduce the burden of type 2 diabetes. Clinical Trial: ACTRN12615000931572